United Continental Holdings Inc (NYSE:UAL), SouFun Holdings Ltd (NYSE:SFUN) and TRW Automotive Holdings Corp. (NYSE:TRW) are the market’s top gainers midday. On the losing end are Potbelly Corp (NASDAQ:PBPB), Lumber Liquidators Holdings Inc (NYSE:LL) and Sarepta Therapeutics Inc (NASDAQ:SRPT).

Potbelly

United Continental Climbs

United Continental Holdings Inc (NYSE:UAL) is today’s top midday gainer, its price surging +8.19% after reporting a rise in an important revenue measure for the second quarter. The airline holding company owns subsidiaries United Airlines and Continental is a favorite among a number of billionaire investors, including David Tepper, Leon Cooperman and George Soros. Its price is up +15.23% YTD.

SouFun Holdings Ltd (NYSE:SFUN) climbed +7.16% today after announcing strategic cooperation agreements with two Chinese new home agency companies. Steve Mandel picked up 4.4 million SFUN shares during Q1, and despite today’s jump, is still waiting for the investment to pay off, as the stock is down -37.68% YTD.

TRW Automotive Holdings Corp. (NYSE:TRW). takes the last spot on today’s list of midday gainers. Its price jumped +7.1% following reports that the auto parts supplier is in early-sage sale talks with German company ZF Friedrichshafen AG. TRW has climbed a healthy +31.36% since the start of 2014. During Q1, Ray Dalio picked up 9,000 of the company’s shares.

Potbelly, Lumber Liquidators Disappoint

Shares of Potbelly Corp (NASDAQ:PBPB) dove -23.96% midday today, following yesterday’s bleak report on its latest quarter. The sandwich chain slashed its 2014 expectations as well. The Tiger Global pick has fallen -63.08% over the past year.

Lumber Liquidators Holdings Inc (NYSE:LL) plunged -21.67% today, marking a second day of losses for the hardwood flooring retailer. The Steve Mandel holding reported disappointing results on Wednesday, missing the mark on sales and earnings. Its price has declined -45.42% in 2014.

Sarepta Therapeutics Inc (NASDAQ:SRPT) had a rough start to the day as well. By midday, its price had fallen -17.43%. This morning, the company released 144-week data from one of its studies, which didn’t prove as optimistic as many had hoped. George Soros has had a position in the biopharmaceutical firm for several quarters, though he cut back his allocation significantly in Q1.